Market Overview

UPDATE: BMO Capital Downgrades Pfizer

Share:
Related PFE
Drug Trials Heating Up In The Breast and Ovarian Cancer Treatment Space
Jim Cramer Gives His Opinion On Tesla, Pfizer And UnitedHealth

In a report released Monday, BMO Capital analyst Alex Arfaei downgraded Pfizer (NYSE: PFE) from Outperform to Market Perform while reducing its price target from $34 to $31.

Analysts at BMO stated Pfizer has "limited growth prospects." Pfizer's new drug releases do not outweigh its mature franchises heavily declining dividend; backpacks create some short-term support, but not enough for growth maintenance.

Latest Ratings for PFE

DateFirmActionFromTo
Dec 2016GuggenheimInitiates Coverage OnNeutral
Nov 2016BarclaysUpgradesEqual-WeightOverweight
Nov 2016ArgusDowngradesBuyHold

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: Alex Arfaei BMO CapitalDowngrades Price Target Analyst Ratings

 

Related Articles (PFE)

View Comments and Join the Discussion!